Immune Checkpoint Inhibitors Market Expected to Touch US$ 30,000 Mn by 2026

Global Market Study
on Immune
Checkpoint
Inhibitors: North America’s Dominance in the Market will Remain
Unchallenged during 2017 - 2026
As projected by a new report published by Persistence Market Research (PMR),
the global immune checkpoint inhibitors market will exhibit a spectacular
expansion over the forecast period, 2017 to 2026. Global sales of immune
checkpoint inhibitor drugs are estimated to surpass US$ 30,000 Mn in revenues
by 2026-end.
Immune Checkpoint Inhibitors are Attracting Interests of Scientists and
Drug Developers
Cancer has become one of the major causes of deaths worldwide. Oncology
research is considered to be a vast field, with several disease indications
including few orphan/rare forms. Significant unmet requirements exist for
cancer therapeutics, albeit oncology’s significant contribution based on drug
development. Drug developers across the globe are now shifting their focus
toward immunotherapeutics, wherein a human body’s immune system is
leveraged to fight cancer. Various classes of immunotherapeutics such as
immune checkpoint inhibitors are now attracting interests of scientists and drug
developers. A number of academic institutes and industry contributors are
making investments in research and development activities concerning immune
checkpoint inhibitors.
With an opportunistic pipeline of development, the market is characterized by
participation of various well-established as well as niche market players over a
common platform. In a bid to gain a firm foothold in the market, various
stakeholders are entering into collaborations for increasing their portfolio and
global presence. For example, Dynavax Technologies Corporation and Merck
are together investigating potential synergistic effects of drug developed by the
combination of Dynavax’s SD-101 with Merck’s two immunotherapies viz.

MK-1966 and Keytruda. Various niche players in the market are also exploring
immune checkpoint inhibitors’ potential in treating patients with cancer through
the development of next-generation immune checkpoint inhibitors therapy.
Browse Full Research Report:
https://www.persistencemarketresearch.com/market-research/immunecheckpoint-inhibitors-market.asp
North America and Europe to Lead Global Immune Checkpoint Inhibitors
Market in Terms of Revenues
In terms of revenues, North America and Europe will continue to lead the
global immune checkpoint inhibitors market, however the latter will register a
relatively faster expansion through 2026. In addition, Asia-Pacific excluding
Japan (APEJ) is projected to ride on the highest CAGR in the market through
2026, followed by Japan. Growth of the market in APEJ can be highly
attributed to rising number of research collaborations between international
players and companies in this region. However, the market in Japan will
account for comparatively larger revenues than that in APEJ by 2026-end.
Although PD-1 among drug class will continue to be the most lucrative, sales of
PD-L1 are projected to register the highest CAGR in the global immune
checkpoint inhibitors market through 2026. PD-L1 have been deemed
successful in treating Merkel cell carcinoma, non-small cell lung cancer, and
bladder cancer. In addition, a number of studies are being carried out for use of
PD-L1 inhibitors for various other types of cancer. CTLA-4 are anticipated to
remain the least lucrative drug class of immune checkpoint inhibitors
throughout the forecast period.
Request and Download Sample Report@
https://www.persistencemarketresearch.com/samples/20122
Key Research Findings from PMR’s Report on Immune Checkpoint
Inhibitors
Urothelial carcinoma and squamous cell carcinoma are projected to be the
fastest growing therapeutic applications of immune checkpoint inhibitors and
are collectively poised to account for over 40% revenue share of the market by
2026-end. Sales of immune checkpoint inhibitors for treating colorectal cancer
and blood cancers are also expected to witness a robust expansion through 2026.
In terms of revenues, hospital pharmacies will continue to be the largest
distribution channels for immune checkpoint inhibitors, owing to increasing

number of hospital admissions associated with cancer.
Key players identified by PMR’s report on the global immune checkpoint
inhibitors include Xinapse Systems Ltd., Toshiba Medical Systems Corporation,
Siemens Healthineers, Sciencesoft USA Corporation, Mirada Medical Limited,
Sanofi, Pfizer, Inc., Novartis AG, Merck KGaA, Merck & Co., Inc., Incyte
Corporation, F. Hoffman-La Roche, Celldex Therapeutics, Bristol-Myers
Squibb, and AstraZeneca.
Download and View Report TOC, Figures and Tables @
https://www.persistencemarketresearch.com/market-research/immunecheckpoint-inhibitors-market/toc
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our
research model is a unique collaboration of data analytics and market research
methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from
multi-dimensional sources. By deploying real-time data collection, big data, and
customer experience analytics, we deliver business intelligence for
organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com